Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

US Food and Drug Administration approval of esketamine and brexanolone
Ioana A. Cristea, Florian Naudet
The Lancet Psychiatry (2019) Vol. 6, Iss. 12, pp. 975-977
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Bo Han, Xiang‐Hong He, Yanqing Liu, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 3, pp. 1522-1586
Closed Access | Times Cited: 319
Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications
Zezhi Li, Meihua Ruan, Jun Chen, et al.
Neuroscience Bulletin (2021) Vol. 37, Iss. 6, pp. 863-880
Open Access | Times Cited: 244
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 163
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 117
A Look at the Importance of Chirality in Drug Activity: Some Significative Examples
Jessica Ceramella, Domenico Iacopetta, Angelica Franchini, et al.
Applied Sciences (2022) Vol. 12, Iss. 21, pp. 10909-10909
Open Access | Times Cited: 71
Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
Octavian Vasiliu
Experimental and Therapeutic Medicine (2023) Vol. 25, Iss. 3
Open Access | Times Cited: 45
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Kyle A. Brown, Todd D. Gould
Molecular Psychiatry (2024) Vol. 29, Iss. 4, pp. 1114-1127
Open Access | Times Cited: 17
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Konstantinos Ν. Fountoulakis, Athanasios Saitis, Alan F. Schatzberg
American Journal of Psychiatry (2025)
Closed Access | Times Cited: 6
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Chiara Gastaldon, Emanuel Raschi, John M. Kane, et al.
Psychotherapy and Psychosomatics (2020) Vol. 90, Iss. 1, pp. 41-48
Closed Access | Times Cited: 97
The molecular pathophysiology of depression and the new therapeutics
Haihua Tian, Zhenyu Hu, Jia Xu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 66
Allopregnanolone: An overview on its synthesis and effects
Silvia Diviccaro, Lucia Cioffi, Eva Falvo, et al.
Journal of Neuroendocrinology (2021) Vol. 34, Iss. 2
Open Access | Times Cited: 64
Reporting of harms in clinical trials of esketamine in depression: a systematic review
Tanguy Taillefer de Laportalière, Adeline Jullien, Antoine Yrondi, et al.
Psychological Medicine (2023) Vol. 53, Iss. 10, pp. 4305-4315
Closed Access | Times Cited: 35
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants
Tao Chen, Ling Cheng, Jingwen Ma, et al.
Pharmacological Research (2023) Vol. 194, pp. 106837-106837
Open Access | Times Cited: 26
Enhanced antidepressant effects of BDNF-quercetin alginate nanogels for depression therapy
Dong Xu, Li-Na Gao, Xujiao Song, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 26
Expanding the Role of Chiral Drugs and Chiral Nanomaterials as a Potential Therapeutic Tool
Sourabh Satapathy, Shivam Kumar, Balak Das Kurmi, et al.
Chirality (2024) Vol. 36, Iss. 7
Closed Access | Times Cited: 11
Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity
Dong Xu, Yu‐Ren Lu, Na Kou, et al.
International Journal of Pharmaceutics (2020) Vol. 586, pp. 119550-119550
Closed Access | Times Cited: 59
An open science pathway for drug marketing authorization—Registered drug approval
Florian Naudet, Maximilian Siebert, Rémy Boussageon, et al.
PLoS Medicine (2021) Vol. 18, Iss. 8, pp. e1003726-e1003726
Open Access | Times Cited: 49
Looking for Novelty in an “Old” Receptor: Recent Advances Toward Our Understanding of GABAARs and Their Implications in Receptor Pharmacology
David Castellano, Ryan D. Shepard, Wei Lü
Frontiers in Neuroscience (2021) Vol. 14
Open Access | Times Cited: 46
New drug approvals for 2019: Synthesis and clinical applications
Shuo Yuan, Bin Yu, Hong‐Min Liu
European Journal of Medicinal Chemistry (2020) Vol. 205, pp. 112667-112667
Closed Access | Times Cited: 49
Are we repeating mistakes of the past? A review of the evidence for esketamine
Mark Horowitz, Joanna Moncrieff
The British Journal of Psychiatry (2020) Vol. 219, Iss. 5, pp. 614-617
Open Access | Times Cited: 43
Overview of treatment-resistant depression
Cheng‐Ta Li
Progress in brain research (2023), pp. 1-23
Closed Access | Times Cited: 15
The Role of Glutamate Underlying Treatment-resistant Depression
Jeongseop Kim, Tae-Eun Kim, Seung‐Hwan Lee, et al.
Clinical Psychopharmacology and Neuroscience (2023) Vol. 21, Iss. 3, pp. 429-446
Open Access | Times Cited: 13
Nanocarrier drug delivery system: promising platform for targeted depression therapy
Xiaoying Feng, Ping Jia, Ding-Ding Zhang
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Approval of esketamine for treatment-resistant depression
Jaskaran Singh, Ella Daly, Maju Mathews, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 3, pp. 232-235
Open Access | Times Cited: 34
Optimum dose of spinal ropivacaine with or without single intravenous bolus of S-ketamine during elective cesarean delivery: a randomized, double-blind, sequential dose-finding study
Xiaoyu Zhang, Jianwei Wang, Xiaohu An, et al.
BMC Pregnancy and Childbirth (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top